论文部分内容阅读
Ramipril是长效ACE(血管紧张素转换酶)抑制剂,它与captopril及enalapril药效学性质相似。文章使用了Ussing Chamber体系对Ramipril的小肠转运机制进行了研究。同时研究了头孢菌素(CFX)和乙酰水扬酸(ASA)对Ramipril小肠吸收的影响。CFX为β-内酰胺类抗菌素,研究已证实其和ACE抑制剂在小肠的转运载体相同。临床实验证明ASA影响ACE抑制剂的药代动力学性质。文章结果表明:Ramipril和captopril等ACE抑制剂的肠转运机制有所不同,没有明显的主动转运特点。CFX不抑制ramipril的肠转运。ASA对ramipril的肠转运也没有明显的影响。但是,ramipril确能抑制CFX的肠转运。所以Ramipril可能为一个被动吸收的ACE抑制剂,并不依靠小肠的肽载体进行转运。
Ramipril is a long-acting ACE (angiotensin-converting enzyme) inhibitor that has pharmacodynamic properties similar to those of captopril and enalapril. The article uses the Ussing Chamber system to study the intestinal transit mechanism of Ramipril. The effects of cephalosporin (CFX) and acetylsalicylic acid (ASA) on the intestinal absorption of Ramipril were also studied. CFX is a beta-lactam antibiotic that has been shown to be the same as the ACE transporter in the small intestine. Clinical trials demonstrate that ASA affects the pharmacokinetic properties of ACE inhibitors. The results show that: ACE inhibitors such as Ramipril and captopril intestinal transit mechanism is different, there is no obvious active transport characteristics. CFX does not inhibit intestinal transport of ramipril. ASA also had no significant effect on intestinal transport of ramipril. However, ramipril did inhibit intestinal transit of CFX. So Ramipril may be a passive absorption of ACE inhibitors, and does not rely on intestinal peptide carrier for transport.